Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL27926628 | 0.95 | SLC7A5 (0.36) | SLC1A5CYP3A4SLC7A5IDO1CYP1A2 | |
| SCHEMBL874924 | 0.94 | SLC1A5 (0.38) | SLC1A5CYP3A4SLC7A5IDO1CYP1A2 | |
| Glycine SCHEMBL3967554 | 0.91 | SLC1A5 (0.35) | SLC1A5CYP3A4SLC7A5IDO1CYP1A2 | |
| Histidine SCHEMBL584583 | 0.88 | SLC7A5 (0.42) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL21331899 | 0.88 | SLC7A5 (0.42) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL19209935 | 0.88 | SLC7A5 (0.42) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL584582 | 0.88 | SLC7A5 (0.42) | CYP3A4SLC7A5CYP1A2 | |
| Glutamic Acid SCHEMBL4229342 | 0.88 | CYP1A2 (0.43) | SLC1A5CYP3A4SLC7A5IDO1CYP1A2 | |
| Histidine SCHEMBL7521146 | 0.84 | SLC7A5 (0.37) | SLC1A5CYP3A4SLC7A5IDO1CYP1A2 | |
| Lysine SCHEMBL18297985 | 0.83 | GSR (0.46) | SLC1A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240352-A2 | MOLECULES DERIVED FROM MECHANISM BASED DRUG DESIGN | eXegenics Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045836-A2 | MOLECULES DERIVED FROM MECHANISM BASED DRUG DESIGN | CYTOCLONAL PHARMACEUTICS, INC. (US) | 2001-06-28 | — | — | WO | disclosed |